Compare Huntington Bancshares Incorporated (HBAN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Heron Therapeutics Inc — how do they compare? Huntington Bancshares Incorporated trades at $15.29 (market cap $31.04B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Huntington Bancshares Incorporated is far larger — about 456.4× Heron Therapeutics Inc's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Heron Therapeutics Inc for 35 Days on average.
| HBAN | HRTX | |
|---|---|---|
Market Cap | $31.04B | $68.01M |
Volume | 23,864,172 | 1,891,941 |
Sector | Financials | Health |
52-Week High | $19.27 | $1.49 |
52-Week Low | $15.02 | $0.27 |
Typical Hold Time | 52 Days | 35 Days |
Enterprise Value | $49.57B | $174.75M |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.28, up 0.73% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bearish technical signal with key support at $15 and resistance at $16, while fundamentals show a P/E of 11.82 and net income margin of 24.77%. Recent news highlights a cut in 2027 earnings outlook due to interest rate pressures, though the company maintains shareholder returns via dividends and buybacks.
The outlook for HBAN is cautious, with near-term headwinds from margin compression and loan growth challenges offset by a solid balance sheet and analyst consensus price target of $19.60. Risks include persistent interest rate pressures and competitive lending markets, but the stock offers value appeal with a dividend yield and institutional support.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
